Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
FDA grants marketing approval for Lundbeck's Sabril (vigabatrin)
Lundbeck, 08/24/09
H. Lundbeck A/S announced that the US Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril Tablets and Oral Solution. Lundbeck Inc. plans to launch Sabril in the US during the third quarter of 2009, with an extensive Risk Evaluation and Mitigation Strategy (REMS) program as required by the FDA and created in collaboration with the agency.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09
Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


